SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. QJM 1948; 17: 175202.
  • 2
    Jennette C, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 18792.
  • 3
    Watts RA, Jolliffe VA, Carruthers DM, Lockwood M, Scott DGI. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1996; 39: 120812.
  • 4
    Guillevin L, Jarrousse B, Lok C, Lhote F, Jais JP, Du DLTH, et al, and the Cooperative Study Group for Polyarteritis Nodosa. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange: a prospective randomized trial of 71 patients. J Rheumatol 1991; 18: 56774.
  • 5
    Guillevin L, Fain O, Lhote F, Jarrousse B, Huong DLT, Bussel A, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome: a prospective, randomized trial in 78 patients. Arthritis Rheum 1992; 35: 20815.
  • 6
    Guillevin L, Lhote F, Jarrousse B, Fain O. Treatment of polyarteritis nodosa and Churg-Strauss syndrome: a meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris) 1992; 143: 40516.
  • 7
    Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53: 3347.
  • 8
    Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Généreau T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: a prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 163845.
  • 9
    Guillevin L, Cordier J-F, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 218798.
  • 10
    Guillevin L, Lhote F, Amouroux J, Ghérardi R, Callard P, Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the Polyarteritis Nodosa Group. Br J Rheumatol 1996; 35: 95864.
  • 11
    Hagen C, Daha MR, Hermans J, Andrassy K, Csernok E, et al. Diagnostic value of standardized assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998; 53: 74753.
  • 12
    Jarrousse B, Guillevin L, Bindi P, Hachulla E, LeClerc P, Nilson B. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993; 11: 61521.
  • 13
    Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholay O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 1728.
  • 14
    Luqmani R, Exley A, Kitas G, Bacon P. Disease assessment and management of the vasculitides. Bailleres Clin Rheumatol 1997; 11: 42346.
  • 15
    Kaplan E, Meier P. Nonparametric estimation for incomplete information. J Am Stat Assoc 1958; 53: 45781.
  • 16
    Peto R, Pike M, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 139.
  • 17
    Wohlwill F. Uber die nur Mikroskopisch erkenbarre Form der Periarteritis nodosa. Arch Pathol Anat 1923; 246: 377411.
  • 18
    Küssmaul A, Maier K. Ueber eine nicht bisher beschreibene eigenthümliche Arterienerkrankung (Periarteritis Nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskelhämung einhergeht. Dtsch Arch Klin Med 1866; 1: 484518.
  • 19
    Savage C, Winearls C, Evans D, Rees A, Lockwood C. Microscopic polyarteritis: presentation, pathology and prognosis. QJM 1985; 56: 46783.
  • 20
    Adu D, Howie A, Scott D, Bacon PA, McGonigle RJS, Michael J. Polyarteritis nodosa and the kidney. QJM 1987; 62: 22137.
  • 21
    Serra A, Cameron J, Turner D, Hartley B, Ogg CS, Neild GH. Vasculitis affecting the kidney: presentation, histopathology and long-term outcome. QJM 1984; 53: 181207.
  • 22
    Schnabel A, Reuter M, Gross W. Significance of low-grade alveolar bleeding in ANCA-associated vasculitides (abstract). Clin Exp Immunol 1998; 112: S65.
  • 23
    Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989; 135: 92130.
  • 24
    Guillevin L, Lhote F, Brauner M, Casassus P. Antineutrophil cytoplasmic antibodies (ANCA) and abnormal angiograms in polyarteritis nodosa and Churg-Strauss syndrome: indications for the diagnosis of microscopic polyangiitis. Ann Med Interne (Paris) 1995; 146: 54850.
  • 25
    Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol 1997; 36: 12907.
  • 26
    Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Relapses in patients with a systemic vasculitis. QJM 1993; 86: 77989.
  • 27
    Inoue M, Akikusa B, Masuda Y, Kondo Y. Demonstration of microaneurysms of the interlobular arteries of the kidneys in microscopic polyangiitis: a three-dimensional study. Hum Pathol 1998; 29: 2237.
  • 28
    Jennette J, Falk R. Small-vessel vasculitis. N Engl J Med 1997; 337: 151223.